The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Akero Therapeutics Inc shares valued at $483,500 were purchased by PATRICK D LAMY on May 22 ’25. At $48.35 per share, PATRICK D LAMY acquired 10,000 shares.
Also, Yale Catriona sold 10,000 shares, netting a total of over 392,978 in proceeds. Following the sale of shares at $39.30 each, the insider now holds 95,034 shares.
Before that, CATRIONA YALE had added 30,000 shares to its account. In a trade valued at $1,136,400, the Officer bought Akero Therapeutics Inc shares for $37.88 each.
As published in a research note from BofA Securities on January 30, 2025, Akero Therapeutics Inc [AKRO] has been rated up from a Neutral to a Buy and the price target has been revised to $63 from $35. Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in late January. As of November 18, 2024, Citigroup has initiated its “Buy” rating for AKRO.
Analyzing AKRO Stock Performance
During the last five days, there has been a surge of approximately 22.55%. Over the course of the year, Akero Therapeutics Inc shares have jumped approximately 76.02%. Shares of the company reached a 52-week high of $58.40 on 01/27/25 and a 52-week low of $21.34 on 01/14/25.
Support And Resistance Levels for Akero Therapeutics Inc (AKRO)
According to the 24-hour chart, there is a support level at 47.79, which, if violated, would cause prices to drop to 46.61. In the upper region, resistance lies at 50.35. The next price resistance is at 51.72. RSI (Relative Strength Index) is 64.94 on the 14-day chart, showing neutral technical sentiment.
